Ikena Oncology, Inc. (IKNA)

US — Healthcare Sector
Peers: HOWL  EWTX  CELC  CCCC  DSGN  FNCH 

Automate Your Wheel Strategy on IKNA

With Tiblio's Option Bot, you can configure your own wheel strategy including IKNA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol IKNA
  • Rev/Share 0.0
  • Book/Share 2.4018
  • PB 7.1446
  • Debt/Equity 0.049
  • CurrentRatio 13.519
  • ROIC -0.3627

 

  • MktCap 718823820.0
  • FreeCF/Share -0.6047
  • PFCF -24.6324
  • PE -26.9356
  • Debt/Assets 0.045
  • DivYield 0
  • ROE -0.2488

 

  • Rating
  • Score
  • Recommendation
  • P/E Score
  • DCF Score
  • P/B Score
  • D/E Score

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million
IKNA
Published: July 25, 2025 by: GlobeNewsWire
Sentiment: Neutral

The combined company will operate under the name “ImageneBio, Inc.” and will begin trading on Nasdaq under the ticker symbol “IMA” at market open on Monday, July 28, 2025

Read More
image for news Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million

About Ikena Oncology, Inc. (IKNA)

  • IPO Date 2021-03-26
  • Website https://ikenaoncology.com
  • Industry Biotechnology
  • CEO Mark Manfredi
  • Employees 10
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.